Backbone Cyclic Peptidomimetic Melanocortin-4 Receptor Agonist as a Novel Orally Administrated Drug Lead for Treating Obesity
作者:Shmuel Hess、Yaniv Linde、Oded Ovadia、Eli Safrai、Deborah E. Shalev、Avi Swed、Efrat Halbfinger、Tair Lapidot、Ilan Winkler、Yael Gabinet、Avi Faier、Dana Yarden、Zhimin Xiang、Federico P. Portillo、Carrie Haskell-Luevano、Chaim Gilon、Amnon Hoffman
DOI:10.1021/jm701093y
日期:2008.2.1
improved its metabolic stability and intestinal permeability by synthesizing a library of backbone cyclic peptidomimetic derivatives. One analog, peptide 1 (BL3020-1), was selected according to its selectivity in activating the MC4R, its favorable transcellular penetration through enterocytes and its enhanced intestinal metabolic stability. This peptide was detected in the brain following oral administration
源自黑素细胞刺激激素(alphaMSH)及其类似物的四肽序列His-Phe-Arg-Trp导致食物摄入减少,并在与melanocortin-4受体(MC4R)结合时提高了能量利用率。为了利用该序列作为治疗肥胖症的有效药物,我们通过合成骨架环状拟肽衍生物的文库改善了其代谢稳定性和肠通透性。根据其在激活MC4R中的选择性,其通过肠细胞的有利跨细胞穿透作用和增强的肠代谢稳定性来选择一种类似物肽1(BL3020-1)。口服给予大鼠后在大脑中检测到该肽。小鼠单次口服剂量为0.5 mg / kg导致食物消耗减少(相对于对照组,高达48%),持续5小时。每天一次重复口服一次(0.5 mg / kg /天),持续12天可减轻体重增加。研究表明,骨架环化可产生治疗肥胖的潜在药物。